Nasdaq
$0.7697▲ 0.55%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $138.6MShares out 1.800M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 10.2Pre-market26.10.02 21:004Ownership#●●●#●●●
Compass Therapeutics, Inc.
Insider Neil Lerner of Compass Therapeutics, Inc. filed a Form 4 on October 2, 2026, reporting changes in beneficial ownership of securities as of October 1, 2026. This filing serves as an official record of the insider's equity transaction.…more
$0.7697+0.55%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.25Pre-market26.09.25 21:014Ownership
Compass Therapeutics, Inc.
Compass Therapeutics insider Neil Lerner reported a change in beneficial ownership of company securities as of September 24, 2026. This filing serves as a standard notification regarding updates to executive stock holdings.…more
$0.7697+0.55%vs prev closeView filingShare - 9.22Pre-market26.09.22 21:308-KKey event
Compass Therapeutics, Inc.
Compass Therapeutics received feedback from the FDA recommending an additional trial to demonstrate a survival benefit before submitting a BLA for its biliary tract cancer treatment, tovecimig. The company maintains that the existing Phase 2/3 study data is sufficient and intends to continue regulatory engagement with the FDA.…more
$0.7697+0.55%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoClosed26.10.24 17:15#●●●#●●●
Compass Therapeutics Reports Phase 2/3 Results for Tovecimig in Biliary Tract Cancer…more
Compass Therapeutics published Phase 2/3 results for its biliary tract cancer drug, tovecimig, in the Journal of Clinical Oncology. While the study met primary endpoints for response rate and progression-free survival, it did not demonstrate a statistically significant improvement in overall survival.…more
$0.7697+0.55%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.14After-hours26.10.15 05:30
●●●●●●●● ●●●●● ●●●●●●
Compass Therapeutics has granted stock options for 200,000 shares to a new employee as a material inducement for employment. This is a standard compensation practice for talent acquisition and has no significant impact on the stock price.…more
$0.7697+0.55%vs prev close - 9.22Regular26.09.23 03:02
●●●●●●●● ●●●●● ●●●●●●
Compass Therapeutics shares dropped after the FDA recommended an additional survival-benefit trial before the company can submit a BLA for its biliary tract cancer drug. The company disagrees with the need for a new trial, creating regulatory uncertainty that has pressured the stock.…more
$0.7697+0.55%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report